The present invention relates to an interface between a human and a piece of equipment, for example respiratory devices that include a foam-based interfacing structure.
In a number of fields, such as respiratory therapy, apparatus for delivery of therapy includes a rigid component and a soft, cushioning component positioned between a patient and the rigid component.
In the case of a respiratory device, the rigid component may be a mask frame defining a nose and/or mouth-receiving chamber. The mask frame may include a flange around its periphery or other connecting means. The cushioning component may be glued or otherwise coupled to the flange or connecting means.
The cushioning component may form a seal with the skin of the patient in some forms of respiratory therapy. In other devices, for example headphones, it may not be necessary for a seal to be formed.
A first aspect of the invention is to provide a mask assembly with a foam interfacing structure.
Another aspect of the invention is to provide a mask assembly with a foam interfacing structure where at least a part of the foam (e.g., an unskinned part of the foam) is in direct contact with the skin of the mask user.
Another aspect of the invention is to provide a mask assembly with a foam interfacing structure where the foam is unskinned and has a cellular structure of the foam in direct contact with the skin of the mask user.
Another aspect of the invention is to provide a mask assembly with a removable foam interfacing structure.
Another aspect of the invention is to provide a mask assembly with at least two different types of removably replaceable interfacing structures.
Another aspect of the invention is to include a softer interfacing structure having portion adapted for engagement with a more rigid component.
Another aspect of the invention is to provide a respiratory mask assembly including a frame and an interfacing structure wherein the interfacing structure includes a foam-based cushion component and a clip portion adapted for removable engagement with the frame portion.
Another aspect of the invention is to provide a support structure for a cushioning component wherein the support structure supports the cushioning element on one side and allows movement on another side.
Another aspect of the invention relates to a cushion for a respiratory mask including a clip portion and a cushioning component wherein the cushioning component is constructed from a foam material and the clip portion is narrower than the cushioning component.
Another aspect of the invention relates to a respiratory mask assembly including a frame having a channel and an interfacing structure including a clip portion adapted for interference seal and retention in the channel. The interfacing structure includes a cushion component constructed from foam and having a wider width than the clip portion.
Another aspect is a foam-based cushioning component preferably having a first cross-section in a nasal bridge region, a second cross-section in a lip region and a third cross-section in the cheek region.
Another aspect is a method of manufacturing a cushioning component, e.g., die cutting and/or machining, etc.
Another aspect is a method of insert molding a clip component to a cushioning component to form an interfacing structure.
Another aspect is a cushioning component for use with a mask, wherein the cushioning component is constructed of foam material. A patient contacting surface, that is adapted to contact a patient, in use, may have a rounded cross sectional profile and a base surface opposed to the patient contacting surface.
Another aspect is a removable interfacing structure for use with a mask including a cushioning component constructed of foam material wherein a patient contacting surface that is adapted to contact a patient, in use, has a rounded cross sectional profile and a base surface opposed to the patient contacting surface is joined to a clip portion, and wherein the clip portion is adapted to be removably joined to a frame of the mask.
Another aspect is a mask including a removable interfacing structure and a frame, wherein the interfacing structure includes a clip portion and a cushioning component constructed of foam material having a patient contacting surface that is adapted to contact a patient, in use, has a rounded cross sectional profile and a base surface opposed to the patient contacting surface is joined to the clip portion, and wherein the clip portion is adapted to be removably joined to a frame of the mask.
Another aspect is a mask including a frame and an interfacing structure, wherein the interfacing structure includes a clip portion joined to cushioning component, and wherein the frame is more rigid than the clip portion and the clip portion is more rigid than the cushioning portion.
Another aspect is a cushioning component for use with a mask, wherein at least a portion of the cross section of the cushioning component includes an inner side defined by the side facing the centre of the mask, an outer side defined by a side facing away from the centre of the mask and a base side facing the frame or clip portion, wherein the length of outer side is greater than the inner side.
Another aspect is an interfacing structure for a mask including a clip portion joined to a cushioning component, wherein an upper surface of the clip portion is joined to a base surface of the cushioning component and wherein at least a portion of the upper surface is angled to provide a moment force on cushioning component, when force is applied into the cushioning component.
Another aspect is an interfacing structure for a mask including a clip portion joined to a cushioning component, wherein an upper surface of the clip portion is joined to a base surface of the cushioning component and wherein the cross sectional width of the clip portion is less than the cross sectional width of the cushioning component.
Another aspect is a cushioning component for use with a mask, wherein at least a portion of the cross section of the cushioning component includes an inner side defined by the side facing the centre of the mask, an outer side defined by a side facing away from the centre of the mask and a base side facing the frame or clip portion, wherein the outer side further includes at least an upper and a lower portion, wherein the upper portion is positioned at a reduced angle in comparison to the lower portion.
Another aspect is a nasal mask including a frame removably connected to an interfacing structure, wherein the interfacing structure includes a cushioning component constructed of foam material, and wherein the height of the interfacing structure is reduced in relation to region that is adapted to contact the upper lip region of a patient's face.
One aspect of the present technology relates to a respiratory mask including a frame, a foam cushion and a substructure. The mask includes a nose receiving cavity. The cushion includes at least two sides: an inner side wall, which may be a wall at least partially facing the cavity; and an outer side wall. The foam cushion is soft and conforming. The substructure is constructed from a more rigid material. The foam cushion is adapted to form a seal with at least one region of a face of a patient. In use the foam cushion is supported by the substructure. A connecting surface of the substructure is defined. A patient side of the foam cushion is defined. A non-patient side of the cushion is defined. In use the non-patient side of the cushion is arranged adjacent the connecting surface of the substructure. In one form the foam cushion is glued to the substructure. In another form the foam cushion is insert moulded with the substructure. A first region of the face is defined as a corner of the mouth of the patient. A second region of the face is defined as a chin region, or alternatively a lip region of the face of the patient. An interior region of the cushion is defined as the region or cavity into which a nose of a patient is inserted in use.
In one form, a part of the connecting surface in use adjacent the first region is structured in to direct a corresponding portion of the foam cushion in an inward direction towards the interior region of the cushion in the first region in use. The cross-section of the cushion defines a radial axis and a longitudinal axis is normal to said radial axis. Preferably, at least a portion of the foam cushion is adapted to rotate towards the centre of the mask about said longitudinal axis when pressure is applied into the cushion by the patient's face and wherein at least a portion of the outer side wall of said cushion is adapted to form a seal against the face of a patient.
Wherein portions of the cushion rotate or roll inwards towards the centre of the mask. The feature of rolling or rotating inwards may prevent or limits the possibility of the seal “blowing out” when air pressure is applied to the mask cavity. “Blowing out” is defined by the seal between the cushion and the patient's face breaking due to pressure exerted by air pressure lifting the cushion from a sealing relationship with the face.
In one form, a part of the connecting surface in use adjacent the second region is structured to direct the foam in an outward direction away from the interior region of the cushion in the second region in use. The cross-section of the cushion defines a radial axis and a longitudinal axis is normal to said radial axis. Preferably, at least a portion of the foam cushion is adapted to rotate away from the centre of the mask about said longitudinal axis when pressure is applied into the cushion by the patient's face and wherein at least a portion of the outer side wall of said cushion is adapted to form a seal against the face of a patient.
Preferably, further portions of the cushion may rotate inwards or outwards relative to the centre of the mask in positions defined as being proximal to the patient's chin. In regions or portions of the cushion that can rotate or roll inwards and outwards, this rotation may allow for seal to accommodate different sizes of chin and/or accommodate moderate amounts of mouth or jaw movement that may otherwise destruct the seal formed between the mask and the patient's face.
Another aspect of the present technology is a foam cushion for a respiratory mask wherein the cushion includes a face-contacting portion arranged in use to be adjacent the face of the patient.
Preferably in at least some regions of the face contacting portion, a cross section of the cushion tapers from a wider cross-section to a narrower cross-section closer to the face. The tapered portion defines an inside surface adjacent an interior of the cushion and an outside surface. The inside surface and the outside surface may be adjacent, in another form they may be non-adjacent. The inside and outside surfaces may be arranged at an acute angle with respect to one another. In one form in cross-section the outside surface is longer than the inside surface in certain regions of the cushion, preferably in the nasal bridge region, or in the cheek region, or more preferably in both. In one form the inside and outside surfaces have the same length in a chin region. In one form in a lip region the inside surface is longer than the outside surface in cross-section.
In one form, the cushion is structured to at least partially form a seal on an outside surface of a face in a chin region of the cushion. We have found that a tapered sealing portion may improve the seal.
Other aspects are directed to methods for manufacturing the foam cushioning elements described above.
Other aspects, features, and advantages of this invention will become apparent from the following detailed description when taken in conjunction with the accompanying drawings, which are a part of this disclosure and which illustrate, by way of example, principles of this invention.
The accompanying drawings facilitate an understanding of the various embodiments of this invention. In such drawings:
The following description is provided in relation to several embodiments which may share common characteristics and features. It is to be understood that one or more features of any one embodiment may be combinable with one or more features of the other embodiments. In addition, any single feature or combination of features in any of the embodiments may constitute additional embodiments.
In this specification, the word “comprising” is to be understood in its “open” sense, that is, in the sense of “including”, and thus not limited to its “closed” sense, that is the sense of “consisting only of”. A corresponding meaning is to be attributed to the corresponding words “comprise”, “comprised” and “comprises” where they appear.
The term “air” will be taken to include breathable gases, for example air with supplemental oxygen.
The term “seal” will be taken to mean to reduce the flow of air between the pressurized interior of the mask and the ambient conditions to a level sufficient to maintain a therapeutic pressure in the airways to effect treatment. Hence in some cases, there may be an air tight seal, in other cases there may be a small leak.
A mask assembly used to facilitate the delivery of a supply of air or breathable gas to the entrance of the airways of a patient typically includes a generally soft, conforming interfacing structure, at least a portion of which is in contact with the patient's face and a stabilizing structure that positions and retains the interfacing structure in a suitable position with respect to the patient. The mask assembly typically includes some form of anchor point to which various components may be connected, or about which they may be arranged. In this specification, this anchor point will be referred to as the frame.
By way of example, the stabilizing structure of the mask assembly may be called “headgear” and both the headgear and interfacing structure may be connected to a frame. In some forms of mask, the boundary lines between the different components may be blurred. For example, aspects of frame and headgear may be combined.
The interfacing structure may perform two or more functions: (i) a cushioning function, performed by a cushioning component, and (ii) an interconnection function, performed by a cushion-to-frame component or clip portion. Generally, in this specification the term “clip” or “clip portion” may describe the aforementioned clip portion or a cushion to frame component for securing the cushioning component to a frame of a mask.
Forming the interfacing structure from two separate elements enables each to have different properties, such as different densities or air permeabilities as suits their different roles, as will be described in more detail in the following sections. Furthermore, the different properties of different materials can act to influence the other component. For example, a more rigid clip or cushion-to-frame portion can act as a support structure for a softer cushioning component.
However, in another embodiment, the interfacing structure may be constructed from a single component with different properties in different regions of the interfacing structure. Furthermore, the interfacing structure may be formed from more than two components.
The interfacing structure may be constructed and arranged to apply air or breathable gas to both the nose and mouth (a “nose & mouth” or “full-face” mask), or to the just the nose (a “nose” or “nasal” mask), or just the mouth (a “mouth” mask).
The statement “more rigid” may be understood to mean less flexible and/or stiffer.
2.1 Material
In one form, the cushioning component may be made from an unskinned, low density, permeable foam. In a preferred embodiment, the cushion component is constructed from a low resilience viscoelastic polyurethane foam. The cushioning component material may be manufactured from a free rising slabstock foam process. In other embodiments the material may be manufactured by other processes such as molding or other known processes used to produce soft and cellular materials. One or more fabrication steps (known as conversion techniques) may then be applied to the material to partially or completely form the geometry of the cushion component. These conversion techniques are described herein and in other related specifications referenced herein. Such a foam material and conversion techniques are disclosed in PCT Publication Nos. WO 2008/011682, published Jan. 31, 2008, and WO 2008/070929, published Jun. 19, 2008, each of which is incorporated herein by reference in its entirety. In one form, the cushioning component may be formed in whole or in part by a known method such as die cutting. Die cutting is disclosed in PCT Application PCT/AU2009/000262, filed Mar. 4, 2009. In another form the cushioning component may be formed in whole or in part by using other methods such as those disclosed in AU 2008904769 and AU 2008904778.
Most foam material production techniques produce a material that has a substantially skinned material such that the density of the material at the surface is greater than the density of the material's bulk (internal) properties. The utilization of particular manufacturing techniques, such as foam conversion processes involving cutting, may allow the production of a unskinned cushioning component such that the bulk properties of the cellular material are exposed at the surface of the cushioning component, providing a number of advantages to the design, manufacture and performance of the mask assembly.
The unskinned cushion component provides improved sealing, comfort and fit range performance, sealing properties sufficient to not require a silicone membrane, and a unskinned mask assembly that allows utilization of the bulk properties of the unskinned material, e.g., porosity for breathability, fine cell structure for a comfortable feel.
2.2 Shape
The interfacing structure is preferably constructed and arranged to have a three dimensional shape defined in part by a locus of points surrounding and complementary to the entrance to the relevant airways. Furthermore, the interfacing structure has a cross-section chosen at different points around its perimeter to provide efficacy and comfort by being suitably shaped to adapt and conform to the face of the user forming a compression-type seal. In another configuration, a flap-type seal is formed.
The shape of the interfacing structure may be adapted to allow the cushioning component to provide a better fit and seal against the face of the patient.
In an embodiment, the geometry of the cushion may be at least partly determined by the geometry of the frame to which it is to be attached. For example, the general shape of a small size cushion may be different than the general shape of a large size cushion because the small and large size frames may be different, e.g., the small may be more stout or wide while the large may be more elongated and thinner.
2.2.1 Full Face Mask
Preferably, the full face masks depicted in this specification may have cushioning components about 105-110 mm in width (as measured from the outer most edges of the base surfaces); and a length of between 120-150 mm.
Nasal Bridge Region
As shown in
There is a radius r1 at the apex 2010 of the cross section, that may be relatively small or sharp radius at the nasal bridge region NB. For example, radius r1 may be between 1 to 4 mm. This relatively small or sharp radius at radius r1 provides the advantage that the cushioning component is kept away from the patient's eyes, especially when the cushioning component is compressed and inflated with air pressure in use. The relatively small or sharp radius at radius r1 may also enable minimal contact of the mask with the patient's skin, so as to make the mask feel more comfortable and less obtrusive.
As best shown in
Additionally, the generally triangular cross section of the cushioning portion may also additionally be defined has having three sides: an inner side which faces into the centre of the mask; an outer side facing away from the centre of the mask and a base surface, which may be adapted to be joined to a clip portion, at least in part.
The outer side of surface of the cushioning portion is generally adapted to be longer than the inner surface. This may allow the cushioning component to, in effect, roll, bend or move inwards. The rolling motion leads to an extension of the sealing surface formed between the skin of the patient and the cushioning component. As the cushioning component is depressed, the contact region against the patient's skin is lengthened from the minimum contact point which is the apex to at least partially extending along the outer surface or side of the cushioning component.
For example, the apex of the triangle that contacts the user's face (
The rolling effect or the turning moment force, when the mask is pressed onto the face, can be also increased or assisted the positioning or shape of the clip portion attached to the cushioning portion. Preferably, the clip portion 3234 may be joined to the base surface of the cross section of the cushioning component. More preferably, the clip is mounted proximal to the outer side of the cushioning component, and provides little or no support relative to the inner side of the cushioning component. Preferably, the clip portion may not generally support the inner side of the cushioning component.
Preferably, the clip portion includes a stepped configuration when viewed in accordance with its cross section. In
Preferably, the clip portion is joined to the cushioning component by an upper side. The upper side of the clip portion may be shaped to assist with: sealing of the cushioning component; comfort; and/or the aforementioned rolling effect of the cushioning component. In
Preferably, the upper corner which is adapted to engage the nasal bridge of the patient, the upper surface of the clip portion is flat and not angled towards to the centre of the mask. This is generally because the region around the nose doesn't require as much “roll” as the sealing area against the sides of the nose is relatively long compared the regions around or about the cheeks of the patient. This feature is demonstrated in
Preferably, the nasal bridge region also includes a modification to the base surface, wherein the base surface has been reduced or shortened to thereby reduce the volume of foam material rolled inwards at the nasal bridge.
As shown in
As shown on
The most preferred maximum width of the nose bridge region (as measured along the base surface) is 22 mm and most preferred maximum height of the cushioning component at the nose bridge position is approximately 24 mm.
Bottom Lip Region
As shown in
Preferably, in the embodiment depicted in
As best shown in
In
Alternatively, patient contacting surface 940 may have apex 950 that may first contacts the patients face and anchors the cushion in the dimple of the chin or curvature between the lower lip and chin region. Apex 950 may have a relatively small radius r2 when compared to that radius r2 shown in
Additionally, as shown in
The preferred maximum width of the cushioning component as measured in respect of the base surface is generally about 35 mm in relation to the bottom lip region. The preferred maximum height of the cushioning component is generally about 26 mm in relation to the bottom lip region.
In
Side of Nose Region
As shown in
Preferably, the outer side is longer than the inner side. Also preferably, the angle formed between the outer side and the base surface is generally less than the angle formed between the inner side and the base surface.
The most preferred maximum width of the side of nose region (as measured along the base surface) is 22 mm and most preferred maximum height of the cushioning component at the side of nose position is approximately 24 mm.
Cheek Region
As shown in
A similar arrangement is shown in
Preferably, the outer side of cushioning component is longer than the inner side. Also preferably, the angle formed between the outer side and the base surface is generally less than the angle formed between the inner side and the base surface.
The most preferred maximum width of the cheek region (as measured along the base surface) is 23 mm and most preferred maximum height of the cushioning component at the cheek region is approximately 24 mm.
Additionally, when the clip portion is joined or mounted to the cushioning component, the apex of the cushion is additionally offset towards the centre or middle of the mask. In the described embodiments, the apex may be offset to the extent that it overhangs the point formed between the inner side and the base surface.
2.2.2 Nasal Mask
Preferably, the cushioning component of the nasal mask shown in respect of these embodiments is preferably: 70-75 mm in length (when measured from the outer most edges of the base surface of the cushioning component); and the width of the cushioning component is approximately 75-80 mm.
Nasal Bridge Region, Side of Nose Region and Cheek Region
The nasal bridge region 4200, side of nose region 4300 and cheek region 4400 may be generally similar to that described above for a full face cushion.
The preferred height of the cushioning component at the region designated to correspond to the nasal bridge of the patient is approximately 22 mm. The height of the cushioning component at the position designated to meet the side of the nose is approximately 25-27 mm. The height of the cushioning component at the position designated to meet the patient's cheek regions is approximately 27 mm.
The preferred width of the cushioning component in the side of nose regions is typically about 20 mm. Whereas the preferred width of the cushioning component in the cheek regions is typically about 18 mm.
Upper Lip Region
As shown in
The preferred width of the cushioning component in the upper lip region is typically about 16 mm. The width of the cushioning component in the upper lip region may be 10-20 mm. The width of the cushioning component in the upper lip region may be 15-20 mm. The width of the cushioning component in the upper lip region may be 12-20 mm. The width of the cushioning component in the upper lip region may be 10-15 mm. The width of the cushioning component in the upper lip region may be 10-18 mm. The width of the cushioning component in the upper lip region may be 10-14 mm.
The preferred height of the cushioning component at the region designated to correspond to the upper lip of the patient is approximately 18 mm. The height of the cushioning component in the upper lip region may be 10-20 mm. The height of the cushioning component in the upper lip region may be 10-25 mm. The height of the cushioning component in the upper lip region may be 15-20 mm. The height of the cushioning component in the upper lip region may be 16-23 mm.
Fit Range
Because of the wide range of sizes and shapes of different people's faces, it is a continual challenge for mask designers to determine the least number of mask shapes required to fit the broadest range of patients. In one ideal form, a single mask shape would fit all patients.
A mask assembly in accordance with the invention provides an improved fit range. This maybe preferably achieved by combining a more comfortable and compliant material with a more anatomically neutral geometry that seals against a wider range of facial anatomy for a given shape.
The versatility of a chosen cushion shape, and hence its fit range performance, is also enhanced by the ‘hovercraft’ behavior exhibited by the cushion. In this context the “hovercraft” behavior is generally defined by the air pressure in the cavity of the mask when the air pressure in cavity of the mask is greater than the outside environmental air pressure and thereby allows the mask to float on the face of the wearer. The pressure seal is preferably formed by the cushioning component. This feature may enhance the ease and speed of fitting the mask.
When pressurized with air the cushion material has extra extensibility compared to other known cushion materials. The soft flexible cells in the foam material effectively stretch when inflated allowing the material the freedom to enlarge. This allows the cushion material to have an extra dimension of conformability over other cushion materials known in the art e.g. silicone, by being able to expand and morph to facial anatomy when inflated with air pressure. This is, in part, also achieved by combining an expandable open-cellular structure in direct communication with the air that is providing the positive airway pressurization. It is the flow of air through the sealing material that forms a fine layer of pressurized air between the facial skin, and the flexible nature of the cushion material that enables this hovercraft effect, hence making it easier to fit to the face. The foam being less sticky than silicone also has a significant advantage in achieving an easy, fast and comfortable fit.
2.3 Method of Manufacturing
The following manufacturing techniques may be used to create a range of shapes and cross-sections as may be required for different facial shapes. Since the cushioning component is preferably made from unskinned foam, one or more cutting processes may be used to create the part, such cutting processes including die cutting, and/or machining, etc. Alternatively the cushioning component may be molded with measures taken in the process to minimize the skin on the foam component, or the skin being subsequently removed from the molded component in a post process e.g. machined. Preferably, the foam material used in the herein described embodiments may be an open and closed cell foam. The foam material used may be an open cell foam. The foam material used may be a closed cell foam.
2.3.1 Die Cutting
In the illustrated embodiment shown in
To create a curved backed cushion, that for example matches the shape of a curved clip without stretching or deformation, the cushion component may be die cut from a foam sheet that is cut into a curved shape rather than a flat sheet. The curved sheets may be formed from a known process referred to as contour cutting, where a foam block is cut into curved sheets by being fed into an oscillating blade that changes position and orientation during the cutting process.
In addition to die cutting or in the alternative, the cushioning component, e.g., as shown in
3.1 Material
The cushion-to-frame component may be made from a material that has greater structural integrity than the cushioning component. In a preferred embodiment the clip is made from polyurethane foam that has higher hardness, higher density, and lower permeability than the foam used for the cushioning component. The clip/cushion-to-frame component may be formed in a mould giving rise to a harder, denser, lower permeability foam having a skin. In an alternatively preferred embodiment, the clip may be constructed of a non-foamed polymer, for example (but not limited to), nylon, polycarbonate, polypropylene.
Preferably, the clip portion or clip component may be of reduced hardness or increased flexibility in comparison to the frame portion of the mask to which it is to connected or secured with.
3.2 Shape
The clip 934 is shown generally in
The clip may also be made flat. The cushion can therefore also be made with a flat back to match the clip. The overall intended shape of the interfacing structure (combination of clip and cushion) can therefore be alternatively achieved by the flat clip and cushion being deformed and retained into a curved frame. This embodiment allows clip to be manufactured flat which can have several advantages including ease of handling and alignment during manufacture, packaging and transportation. The clip can therefore be formed by alternative methods e.g. die cutting from flat sheet material.
The clip may also be made curved. This may be achieved by several means including molding directly into a curved shape, die cutting from curved (contour cut) sheet, or heat forming a flat clip die cut from a thermoformable material. Having the clip curved allows ease of alignment and assembly to a curved frame, as well as giving the cushion a curved shape if the cushion is made from a process that results in it having a flat back.
In a preferred embodiment the clip is made from molded polyurethane. The cushion contacting surface 935 is generally smooth so that it can continuously join and seal to the underside of the cushion. Cushion contacting surface 935 has a lip 935a to enable alignment of the clip to the frame.
Frame contacting surface 937 has three alignment tabs 938 protruding from its surface that engage with the frame. There may be any number of alignment tabs 938 to aid the patient in aligning the interface structure with the anchoring structure. It should also be appreciated that the clip need not have alignment tabs 938 to engage the clip with the frame.
The clip may also be made to incorporate features that engage the frame to aid retention of the interfacing structure to the frame. Examples include, but are not limited to, surface roughening, ribs, notches, snaps etc.
3.3 Method of Manufacturing
The clip component may be separately formed as will be now described, or insert molded as will be described later in this specification.
By way of example,
The bottom half 1565 includes a cavity 1567 adapted to receive the material (e.g., foaming mixture) that will form the clip portion. Also, the center section 1568 of the bottom half 1565 accommodates a separate insert that acts as a manual ejection feature after molding. The top half 1560 provides a surface 1562 that will form the side of the clip portion for interfacing or joining with the cushion component.
The top and bottom halves 1560, 1565 of the tool are constructed and/or arranged to facilitate demolding of the clip portion from the tool so that the clip portion will not adhere to the tool. For example, the top and bottom halves 1560, 1565 may be constructed of a material from which the mold material (e.g., foaming mixture) may be removed (e.g., high density polypropylene, silicone). Alternatively, a demolding agent (e.g., wax) may be provided to the top and bottom halves to facilitate demolding.
An alternative demolding aid may be a release film that lines the tool and releases from the clip material easily after molding. In a preferred embodiment the release film may double, in whole or in part, as the packaging for the interfacing structure such that the product leaves the molding process already packaged. In another embodiment the clip includes a tab at one or a number of locations that facilitates gripping of the part for demolding during the manufacturing process. This tab feature may also double as an alignment feature for assembly and a gripping feature for disassembly for the user of the mask assembly.
In another embodiment the clip may include a tab feature that includes an end of life indicator for the interfacing structure.
4.1 Relative position
In accordance with an embodiment of the invention, a range of different arrangements of clip portions and cushion components may be provided. For example, the width of the clip portion may preferably match or be less than the maximum width of the cushion component, the width of the cross section of clip portion may be less than the width of the cross section of the cushion component. In these different configurations with different relative widths, the clip portion provides different forms of support to the cushion component.
Wherein the width of the cross section of the clip portion is less than the width of the cross section of cushion component, the clip portion and cushion component may be arranged such that (i) the outer perimeter of the clip portion and cushion component align (hides hardness of clip portion and provides desired freedom of movement in the cushion component), (ii) the inner perimeter of the clip portion and the cushion component align, or (iii) neither the inner or outer perimeter of the clip portion and the cushion component align.
Similarly, wherein the width of the clip portion is greater than the width of the cushion component, the clip portion and cushion component may be arranged such that (i) the outer perimeter of the clip portion and cushion component align, (ii) the inner perimeter of the clip portion and cushion component align, or (iii) neither the inner or outer perimeter of the clip portion and the cushion component align.
When the width of the clip portion is less than the width of the cushion component and the outer perimeter of the clip portion aligns with the cushion component, the cushion component may preferably be more able to flex in regions or directions not having a clip portion next to it than in regions having a clip portion adjacent to it or supporting it. For example, where the cushion component overhangs the clip portion, that overhanging region of the cushion component has more freedom to move. This arrangement can be more comfortable and more able to adapt to different geometries of a person, and provide the correct vectors to seal the cushion component against the face.
Preferably, the clip portion is to be joined to a cushioning component by a base surface of the cushioning component. It may also be preferably to arrange the clip portion to support the external extremity (relative to the circumference of the mask) of the base surface and to have no or little support inner extremity of the base surface.
When used as part of a respiratory mask, it may be preferable that the inner portion of the cushion component overhang the clip portion. In this arrangement in use, the face of the patient may engage with an unsupported inner edge of the softer cushion component causing it to bend and conform to the individual patient's shape. When the mask engages a patient's face, the cushioning component may roll inwards towards the centre of the mask when pressure is applied on the mask towards the patient's face.
This arrangement is in contrast to prior art cushions (such as the Lifecare™ mask shown in
In an embodiment, as shown in
4.2 Glue
The two layers (i.e., the cushion component and the clip portion) may be adhered to one another using polyurethane hot melt glue or cyanoacrylate.
In alternate embodiments (not shown in Figures) the cushioning portion may be directly glued onto the frame.
4.3 Insert Molding
In a manufacturing process according to an embodiment of the present invention, insert molding may be used to assemble the cushioning component to the cushion-to-frame component. An advantage of this approach include lower cost when compared to other processes such as gluing.
As best shown in
The first portion 1060 of the tool may allow a vacuum to be applied to the cushioning component to retain it in position. For example, as shown in
The first and second portions 1060, 1065 of the tool are arranged so that there will be a region of contact between the cushioning component and the cushion-to-frame component such that they will adhere to one another.
At least a second portion of the tool is constructed and/or arranged to facilitate demolding of the cushion-to-frame component that would otherwise adhere to the tool. Preferably, this is achieved by using a tool constructed of a material from which the foam may be removed (e.g., high density polypropylene, silicone). Alternatively, steel or aluminum tools may be used, provided an appropriate de-molding agent can be used, such as wax (e.g., agent that does not present biocompatibility issues).
In the illustrated embodiment as best shown in
An insert molding manufacturing process according to an embodiment of the invention will now be described in greater detail.
In
In
When the cushion-to-frame component 1034 has cured, the vacuum first portion and second portion are separated as shown in
In an alternative embodiment the cushion and clip are made flat but the cushion is made with sufficient depth to not require curvature to suitably adapt to the face when worn; but rather suitably deforms to the shape of the face due to the softness and depth of the cushion foam.
In another alternative arrangement, a film may be added to the second portion of the tool prior to the addition of the foaming mixture. This film may be structured to facilitate removal of the otherwise adhering cushion-to-frame component. The film may be used to form packaging for the interfacing structure.
In an embodiment, the clip portion of the interfacing structure may be constructed from more rigid and denser foam than the cushion component. For example, the clip portion may be formed from nitrogen blown polyethylene, or some other biocompatible foam having a fine cell-structure. Alternatively, the clip portion could be made from some other polymer or rubber. In an embodiment, the clip portion is adapted to form a cushion-to-frame engagement mechanism and to form a structural support for the cushion component.
Preferably, the cushioning component is less rigid, less stiff or more flexible than the clip portion, which is in turn less rigid, less stiff or more flexible than the frame of the mask. Preferably, the frame gives shape to the mask interfacing structure, wherein the interfacing structure is relatively flexible and less rigid, overall than the frame. This feature adds comfort and also allows the interfacing structure to be easily replaced by the patient or user. Further improvements to the interfacing structure may be made to adapt the shape and configuration to be disposable.
For example,
This arrangement provides a one piece interfacing structure with a cushion component adapted to engage the patient's face and a clip portion adapted to interface with the mask frame.
In one form, a mask system may be provided that includes at least two different forms of interfacing structure chosen from the set of foam-based cushion, silicone-based cushion, and gel-based cushion.
As shown in
The interfacing structure is constructed as described above and arranged for removable interconnection with the rest of the apparatus, for example a respiratory mask.
The ability to removably connect the interfacing structure enables one to replace the interfacing structure should it become soiled, damaged, uncomfortable or otherwise aged as a result of usage. It also facilitates trial or testing of different arrays of interfacing structures which are selected on different patients facial types or features (e.g., narrower face, longer nose, or longer chin, etc.). One form of interfacing structure, for example a foam-based interfacing structure, may be used as a form of “training” system to allow a person to become accustomed to the sensation of wearing and using a mask. A foam-cushion based mask may provide an initially more appealing and comfortable surface for a new patient than a gel or silicone-based cushion. The patient may subsequently switch from the foam-based cushion to a silicone or gel based cushion. In this way, the patient may be more likely to adhere to therapy because they are used to the very soft comfortable feeling of foam.
When applied to respiratory equipment, the interfacing structure is adapted for connection with a mask frame. In use, a seal is formed between the interfacing structure and the frame. This arrangement could be used for both nasal and full-face masks. The seal between the frame and interfacing structure may seal better wherein the clip portion is less rigid or more flexible than the frame.
For example,
5.1 Cushion-to-Frame Engagement Mechanisms
According to an aspect of the invention, the cushion-to-frame engagement and connection mechanism provided by the clip portion may include a channel-type engagement or rib-type engagement.
As shown in
As shown in
When structured to form an interference fit with the mask frame, the clip portion may have the following properties: appropriate rigidity (e.g., less than that of the frame and in one form more rigid than the foam cushion component); non-porous; and/or low compression set (the amount of deformation expressed as a percentage of original dimensions) which a material retains after compressive stress is released (in this way, the clip portion maintains its retention force during its usage life).
Additionally, the clip portion may include an additional extension (not shown) that extends beyond the outer extremity of the frame which is adapted to be gripped by the patient for easier removal of the interfacing structure. Preferably, this extension would be positioned in a region that is easy for the patient to grip such as the nasal bridge of the mask. Preferably, the extension will be small enough not to impede vision of the user or to affect the overall efficiency or seal of the mask. Preferable, the extension may function as a finger grip for the patient to remove or replace the interfacing structure, when desired.
The following provides exemplary materials and properties of the cushion component and clip portion.
6.1 Cushion Component
In an embodiment, the cushion component may be made from polyurethane, be resistance to hydrolysis and/or resistant to microbial attack.
In an embodiment, the cushion component may be air permeable. In an embodiment, the cushion component may not be air permeable.
In an embodiment, the cushion component may be able to maintain its air permeability over a period of use.
Preferably, the cushion component may not emit harmful or odorous volatiles or particulates.
Preferably, the cushion component may be coloured and this colour may not fade.
In one example, properties of the foam cushion component may include: density (relates to other foam properties and affects cost and weight of the cushion, e.g., higher density can reduce air permeability and higher density can increase hardness); air permeability (flow of air through cushion contributes to total mask flow characteristic of the mask which may affect compatibility with PAP devices); hardness (affects comfort and sealing performance); tear resistance (contributes to durability); tensile strength (contributes to durability); and/or tensile stiffness (resists the deforming effects of positive air pressure inside the mask).
6.2 Clip Portion
In one example, properties of the foam clip portion may include: density (affects weight); air permeability (permeability of the foam itself may not be critical if it is molded with a skin that renders it impermeable); hardness (soft and flexible enough to assemble to the frame with an interference fit and seal against the frame); elasticity/viscoelasticity (soft and flexible enough to assemble to the frame with an interference fit and seal against the frame); and/or compression set (should not deform over time to ensure easy assembly/retention).
6.3 Testing Methods
The following provides exemplary testing methods for determining material properties.
6.3.1 Air Permeability
Air permeability is defined as “the rate of air flowing through a foam sample (in L/min)”.
This test measures the flow through a regular shape with a constant cross section, in a manner analogous to a cushion in real use. In the example of
The foam sample is cut normal to cell rise direction as shown in
The wall section of the foam specimen may be rectangular (see
The annular foam sample is held at a defined height between two plates in a Universal Test Machine (e.g., Instron). Air at a given pressure is directed into the centre of the annulus and flows out through the foam. The air flow rate and reaction force of the foam against the plates may be measured.
As shown in
Once set up, attach the top plate to the crosshead of the UTM, zero the load cell of the UTM.
Zero the displacement of the UTM at the uncompressed height of the foam sample, i.e., 30 mm above the base plate sealing surface.
If there is variation of 1 mm or more in the thickness of the samples, then for each sample: (i) assemble the foam sample into the test jig; (ii) lower the crosshead just until a positive force is read on the UTM, e.g., 0.2 N; and (iii) zero the displacement.
Lower the crosshead at 50±20 mm/min until 40% compression displacement is reached.
Immediately record the reaction force, at 0 cmH2O.
Wait 60 seconds and again record the force.
Immediately but gradually adjust the flow generator to 4 cmH2O (and immediately record force and flow rate.
Wait 60 seconds and again record the force and flow rate.
Repeat steps 7 and 8 for 12 cmH2O and 20 cmH2O.
6.3.2 Hardness
Hardness is defines as “force required to indent a test piece of foam to a stated percentage of its original thickness”.
Hardness may be tested using an IDM Universal Test Machine, or equivalent (e.g., see circular flat indenter of
If applicable, precondition the foam as specified in AS 2282.2-1999.
Test the foam according to AS 2282.8-1999 Method A—Indentation force on deflection test.
Report IF40, the reaction force at 40% compression after 60 seconds indentation, H60s.
Also report the reaction force at 40% compression after 2 seconds indentation, H2s.
Report the sag factor or support factor, i.e., the ratio of 65% to 25% IFD value.
6.3.3 Tensile Strength
Tensile strength may be measured using an IDM Universal Test Machine, or equivalent. See
Test both directions, i.e., parallel to and normal to the direction of cell rise.
Apply the following deviations from AS 2282.6-1999:
Do not reject test pieces that break outside the gauge length.
Record whether the test piece did break, did not break or came out of the jaws before maximum elongation was reached.
Three test pieces may be acceptable if the results are consistent (no individual value deviates more than 20% from the mean of the three values).
Select a typical or representative results curve by inspecting the graphs. Select a suitably linear region near the start of the curve. (The start of the curve is more representative of real use than an extremely stretched region and also ensures the result is not affected by the test sample sliding out of the gripping jaws.)
Calculate the change in force over a distance of at least 25 mm and divide by the distance to obtain the stiffness value in N/mm.
For example, the curve in
ktensile=ΔF/Δx=(F50 mm−F25 mm)/(50−25)
6.3.4 Tear Resistance
Tear resistance is defined as the force required to propagate a tear in a pre-cut sample. See
Test according to AS 2282.7-1999 with the following parameters:
The speed of separation of the jaws holding the test piece shall be 200 mm/min.
Test all three directions defined in
Apply the following deviations from AS 2282.7-1999:
Do not use a knife or blade to assist the direction of tear. Allow the foam to tear naturally.
It may not be possible to tear a 50 mm length of foam. Tear as far as possible up to 50 mm.
Total Mask Flow
This test measures the flow through only the foam cushion, by blocking the mask vent all other leak paths. See
The cushion is compressed by 40% of its 30 mm thickness, i.e., 12 mm.
In an embodiment, a mask frame may be integrally molded or formed with the cushion-to-frame component 1034. For example, the second portion 1065 of the tool may be structured to mold the cushion-to-frame component together with the mask frame.
In the illustrated embodiment, a polyurethane foam cushioning component is provided to a polyurethane foam or polyurethane elastomer cushion-to-frame component. In an alternative embodiment, one or both of the components may be constructed of a gel material. For example, both components may be constructed of gel, the cushioning component may be constructed of gel and the cushion-to-frame component may be constructed of foam, or the cushioning component may be constructed of foam and the cushion-to-frame component may be constructed of gel.
While the invention has been described in connection with what are presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the invention. For example the cutting techniques used for the cushioning component may also be used for the clip component, or the interfacing structure. Also, the various embodiments described above may be implemented in conjunction with other embodiments, e.g., aspects of one embodiment may be combined with aspects of another embodiment to realize yet other embodiments. Further, each independent feature or component of any given assembly may constitute an additional embodiment. In addition, while the invention has particular application to patients who suffer from OSA, it is to be appreciated that patients who suffer from other illnesses (e.g., congestive heart failure, diabetes, morbid obesity, stroke, bariatric surgery, etc.) can derive benefit from the above teachings. Moreover, the above teachings have applicability with patients and non-patients alike in non-medical applications.
Number | Date | Country | Kind |
---|---|---|---|
2008904769 | Sep 2008 | AU | national |
2008904778 | Sep 2008 | AU | national |
This application is a continuation of U.S. patent application Ser. No. 14/524,097, filed Oct. 27, 2014, now allowed, which is a continuation of U.S. patent application Ser. No. 12/737,919, filed Mar. 1, 2011, now U.S. Pat. No. 8,869,798, which is the U.S. National Phase of International Application No. PCT/AU2009/001144, filed Sep. 3, 2009, which designated the U.S. and claims the benefit of Australian Provisional Patent Application Nos. AU 2008904769, filed Sep. 12, 2008, and AU 2008904778, filed Sep. 15, 2008, each of which is hereby incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
443191 | Illing | Dec 1890 | A |
781516 | Guthrie, Jr. | Jan 1905 | A |
1081745 | Johnston | Dec 1913 | A |
1125542 | Humphries | Jan 1915 | A |
1192186 | Greene | Jul 1916 | A |
1229050 | Donald | Jun 1917 | A |
1282527 | Bidonde | Oct 1918 | A |
1362766 | McGargill | Dec 1920 | A |
1445010 | Feinberg | Feb 1923 | A |
1610793 | Kaufman | Dec 1926 | A |
1873160 | Sturtevant | Aug 1932 | A |
2353643 | Bulbulian | Jul 1944 | A |
2415846 | Randall | Feb 1947 | A |
2433565 | Korman | Dec 1947 | A |
2625155 | Engelder | Jan 1953 | A |
2706983 | Matheson et al. | Apr 1955 | A |
2931356 | Schwarz | Apr 1960 | A |
3013556 | Galleher | Dec 1961 | A |
3670726 | Mahon et al. | Mar 1972 | A |
3682171 | Dali et al. | Aug 1972 | A |
3739774 | Gregory | Jun 1973 | A |
3754552 | King | Aug 1973 | A |
3815596 | Keener | Jun 1974 | A |
3861385 | Carden | Jan 1975 | A |
3902486 | Guichard | Sep 1975 | A |
3905361 | Hewson et al. | Sep 1975 | A |
3938614 | Ahs | Feb 1976 | A |
3972321 | Proctor | Aug 1976 | A |
3974829 | Tate | Aug 1976 | A |
4006744 | Steer | Feb 1977 | A |
4142527 | Garcia | Mar 1979 | A |
4153051 | Shippert | May 1979 | A |
4156426 | Gold | May 1979 | A |
4248218 | Fischer | Feb 1981 | A |
4263908 | Mizerak | Apr 1981 | A |
4264743 | Maruyama et al. | Apr 1981 | A |
4267845 | Robertson, Jr. et al. | May 1981 | A |
4273124 | Zimmerman | Jun 1981 | A |
4312359 | Olson | Jan 1982 | A |
4367735 | Dali | Jan 1983 | A |
4367816 | Wilkes | Jan 1983 | A |
4406283 | Bir | Sep 1983 | A |
4414973 | Matheson et al. | Nov 1983 | A |
4422456 | Teip | Dec 1983 | A |
4449526 | Elam | May 1984 | A |
4455675 | Bose et al. | Jun 1984 | A |
4493614 | Chu et al. | Jan 1985 | A |
4548200 | Wapner | Oct 1985 | A |
4549542 | Chein | Nov 1985 | A |
4572323 | Randall | Feb 1986 | A |
4587967 | Chu et al. | May 1986 | A |
4601465 | Roy | Jul 1986 | A |
4617637 | Chu et al. | Nov 1986 | A |
4630604 | Montesi | Dec 1986 | A |
4641647 | Behan | Feb 1987 | A |
4660555 | Payton | Apr 1987 | A |
4671271 | Bishop et al. | Jun 1987 | A |
4676241 | Webb et al. | Jun 1987 | A |
4699139 | Marshall et al. | Oct 1987 | A |
4706664 | Snook et al. | Nov 1987 | A |
4711636 | Bierman | Dec 1987 | A |
4713844 | Westgate | Dec 1987 | A |
D293613 | Wingler | Jan 1988 | S |
4753233 | Grimes | Jun 1988 | A |
4755040 | Haslbeck | Jul 1988 | A |
4767411 | Edmunds | Aug 1988 | A |
4774946 | Ackerman et al. | Nov 1988 | A |
4782832 | Trimble et al. | Nov 1988 | A |
4790829 | Bowden et al. | Dec 1988 | A |
4802857 | Laughlin | Feb 1989 | A |
4803981 | Vickery | Feb 1989 | A |
4811730 | Milano | Mar 1989 | A |
4830138 | Palmaer et al. | May 1989 | A |
4838878 | Kalt et al. | Jun 1989 | A |
4899740 | Napolitano | Feb 1990 | A |
4907584 | McGinnis | Mar 1990 | A |
4915105 | Lee | Apr 1990 | A |
4919128 | Kopala et al. | Apr 1990 | A |
4919654 | Kalt | Apr 1990 | A |
4944310 | Sullivan | Jul 1990 | A |
4945907 | Tayebi | Aug 1990 | A |
4960121 | Nelson et al. | Oct 1990 | A |
4966590 | Kalt | Oct 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4971051 | Toffolon | Nov 1990 | A |
4976698 | Stokley | Dec 1990 | A |
4989599 | Carter | Feb 1991 | A |
4996983 | Amrhein | Mar 1991 | A |
5000173 | Zalkin et al. | Mar 1991 | A |
5005571 | Dietz | Apr 1991 | A |
5020163 | Aileo et al. | Jun 1991 | A |
5022900 | Bar-Yona et al. | Jun 1991 | A |
5023955 | Murphy, II et al. | Jun 1991 | A |
5025805 | Nutter | Jun 1991 | A |
5038772 | Kolbe et al. | Aug 1991 | A |
5042478 | Kopala et al. | Aug 1991 | A |
5046491 | Derrick | Sep 1991 | A |
5074297 | Venegas | Dec 1991 | A |
5113857 | Dickerman et al. | May 1992 | A |
5117818 | Palfy | Jun 1992 | A |
5121745 | Israel | Jun 1992 | A |
5127397 | Kohnke | Jul 1992 | A |
5137017 | Salter | Aug 1992 | A |
5138722 | Urella et al. | Aug 1992 | A |
D333015 | Farmer et al. | Feb 1993 | S |
5188101 | Tumolo | Feb 1993 | A |
5191824 | Rathbun, Jr. | Mar 1993 | A |
5207665 | Davis et al. | May 1993 | A |
5220699 | Farris | Jun 1993 | A |
5243709 | Sheehan et al. | Sep 1993 | A |
5243971 | Sullivan et al. | Sep 1993 | A |
5245995 | Sullivan et al. | Sep 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5263939 | Wortrich | Nov 1993 | A |
5265592 | Beaussant | Nov 1993 | A |
5265595 | Rudolph | Nov 1993 | A |
5267557 | Her-Mou | Dec 1993 | A |
5269296 | Landis | Dec 1993 | A |
5271391 | Graves | Dec 1993 | A |
5304146 | Johnson et al. | Apr 1994 | A |
5299599 | Farmer et al. | May 1994 | A |
5335656 | Bowe et al. | Aug 1994 | A |
5349949 | Schegerin | Sep 1994 | A |
5355878 | Griffiths et al. | Oct 1994 | A |
5355893 | Mick et al. | Oct 1994 | A |
5364367 | Banks et al. | Nov 1994 | A |
5372130 | Stem et al. | Dec 1994 | A |
5372388 | Gargiulo | Dec 1994 | A |
5372389 | Tam et al. | Dec 1994 | A |
5372390 | Conway et al. | Dec 1994 | A |
5372391 | Bast et al. | Dec 1994 | A |
5375593 | Press | Dec 1994 | A |
5385141 | Granatiero | Jan 1995 | A |
5394568 | Brostrom et al. | Mar 1995 | A |
5396885 | Nelson | Mar 1995 | A |
5398676 | Press et al. | Mar 1995 | A |
5400776 | Bartholomew | Mar 1995 | A |
5419318 | Tayebi | May 1995 | A |
5425359 | Liou | Jun 1995 | A |
5429683 | Le Mitouard | Jul 1995 | A |
5437267 | Weinstein et al. | Aug 1995 | A |
5441046 | Starr et al. | Aug 1995 | A |
5462528 | Roewer | Oct 1995 | A |
5477852 | Landis et al. | Dec 1995 | A |
5526806 | Sansoni | Jan 1996 | A |
5488948 | Dubruille et al. | Feb 1996 | A |
5509409 | Weatherholt | Apr 1996 | A |
5513634 | Jackson | May 1996 | A |
5513635 | Bedi | May 1996 | A |
5533506 | Wood | Jul 1996 | A |
5538000 | Rudolph | Jul 1996 | A |
5538001 | Bridges | Jul 1996 | A |
5540223 | Starr et al. | Jul 1996 | A |
5560354 | Berthon-Jones et al. | Oct 1996 | A |
5570684 | Behr | Nov 1996 | A |
5592938 | Scarberry et al. | Jan 1997 | A |
5623923 | Bertheau et al. | Apr 1997 | A |
5626814 | Vicino | May 1997 | A |
5647357 | Barnett et al. | Jul 1997 | A |
5653228 | Byrd | Aug 1997 | A |
5655527 | Scarberry et al. | Aug 1997 | A |
5662101 | Ogden et al. | Sep 1997 | A |
5682881 | Winthrop et al. | Nov 1997 | A |
5704345 | Berthon-Jones et al. | Jan 1998 | A |
5707342 | Tanaka | Jan 1998 | A |
5724965 | Handke et al. | Mar 1998 | A |
5735272 | Dillon et al. | Apr 1998 | A |
5740799 | Nielson | Apr 1998 | A |
5752511 | Simmons et al. | May 1998 | A |
5794619 | Edeiman et al. | Aug 1998 | A |
5807341 | Heim | Sep 1998 | A |
5842469 | Rapp et al. | Dec 1998 | A |
5906203 | Klockseth et al. | May 1999 | A |
5918598 | Belfer et al. | Jul 1999 | A |
5921239 | McCall et al. | Jul 1999 | A |
5954049 | Foley et al. | Sep 1999 | A |
5975079 | Hellings et al. | Nov 1999 | A |
6019101 | Cotner et al. | Jan 2000 | A |
6026811 | Settle | Feb 2000 | A |
6044844 | Kwok et al. | Apr 2000 | A |
6082360 | Rudolph et al. | Jul 2000 | A |
6086118 | McNaughton et al. | Jul 2000 | A |
6095996 | Steer et al. | Aug 2000 | A |
6098205 | Schwartz et al. | Aug 2000 | A |
6109263 | Feuchtgruber | Aug 2000 | A |
6112746 | Kwok et al. | Sep 2000 | A |
6119693 | Kwok et al. | Sep 2000 | A |
6119694 | Correa et al. | Sep 2000 | A |
6123071 | Berthon-Jones et al. | Sep 2000 | A |
6123082 | Berthon-Jones | Sep 2000 | A |
6139787 | Harrison | Oct 2000 | A |
6152137 | Schwartz et al. | Nov 2000 | A |
6176164 | Nylander | Jan 2001 | B1 |
6193914 | Harrison | Feb 2001 | B1 |
6196223 | Belfer et al. | Mar 2001 | B1 |
6211263 | Cinelli et al. | Apr 2001 | B1 |
6231548 | Bassett | May 2001 | B1 |
6241930 | Harrison | Jun 2001 | B1 |
6258066 | Urich | Jul 2001 | B1 |
6295366 | Haller et al. | Sep 2001 | B1 |
6328038 | Kessler et al. | Dec 2001 | B1 |
6341606 | Bordewick et al. | Jan 2002 | B1 |
6347631 | Hansen et al. | Feb 2002 | B1 |
6357441 | Kwok et al. | Mar 2002 | B1 |
6358279 | Tahi et al. | Mar 2002 | B1 |
6374826 | Gunaratnam et al. | Apr 2002 | B1 |
6397847 | Scarberry | Jun 2002 | B1 |
6412487 | Gunaratnam et al. | Jul 2002 | B1 |
6412488 | Barnett et al. | Jul 2002 | B1 |
6412593 | Jones | Jul 2002 | B1 |
6419660 | Russo | Jul 2002 | B1 |
6422238 | Lithgow | Jul 2002 | B1 |
6423036 | Van Huizen | Jul 2002 | B1 |
6431172 | Bordewick | Aug 2002 | B1 |
6434796 | Speirs | Aug 2002 | B1 |
6439234 | Curti et al. | Aug 2002 | B1 |
6448303 | Paul | Sep 2002 | B1 |
6467482 | Boussignac | Oct 2002 | B1 |
6467483 | Kopacko et al. | Oct 2002 | B1 |
6470887 | Martinez | Oct 2002 | B1 |
6478026 | Wood | Nov 2002 | B1 |
6482178 | Andrews et al. | Nov 2002 | B1 |
6491034 | Gunaratnam et al. | Dec 2002 | B1 |
6513526 | Kwok et al. | Feb 2003 | B2 |
6530373 | Patron et al. | Mar 2003 | B1 |
6532961 | Kwok et al. | Mar 2003 | B1 |
6536435 | Fecteau et al. | Mar 2003 | B1 |
6561188 | Ellis | May 2003 | B1 |
6561190 | Kwok et al. | May 2003 | B1 |
6561192 | Palmer | May 2003 | B2 |
6561193 | Noble | May 2003 | B1 |
6615832 | Chen | May 2003 | B1 |
6571798 | Thornton | Jun 2003 | B1 |
6579267 | Lynch et al. | Jun 2003 | B2 |
6581601 | Ziaee | Jun 2003 | B2 |
6581602 | Kwok et al. | Jun 2003 | B2 |
6584975 | Taylor | Jul 2003 | B1 |
6595214 | Hecker et al. | Jul 2003 | B1 |
6595215 | Wood | Jul 2003 | B2 |
6607516 | Cinelli et al. | Aug 2003 | B2 |
6627289 | Dilnik et al. | Sep 2003 | B1 |
6631718 | Lovell | Oct 2003 | B1 |
6634358 | Kwok et al. | Oct 2003 | B2 |
6637434 | Noble | Oct 2003 | B2 |
6644315 | Ziaee | Nov 2003 | B2 |
6655385 | Curti et al. | Dec 2003 | B1 |
6663600 | Bierman et al. | Dec 2003 | B2 |
6669712 | Cardoso | Dec 2003 | B1 |
D485905 | Moore et al. | Jan 2004 | S |
6679257 | Robertson et al. | Jan 2004 | B1 |
6679265 | Strickland et al. | Jan 2004 | B2 |
6701927 | Kwok et al. | Mar 2004 | B2 |
6710099 | Cinelli et al. | Mar 2004 | B2 |
6766800 | Chu et al. | Jul 2004 | B2 |
6766817 | da Silva | Jul 2004 | B2 |
6776162 | Wood | Aug 2004 | B2 |
6776163 | Dougill et al. | Aug 2004 | B2 |
6789543 | Cannon | Sep 2004 | B2 |
6805117 | Ho et al. | Oct 2004 | B1 |
6807967 | Wood | Oct 2004 | B2 |
6817362 | Gelinas et al. | Nov 2004 | B2 |
6820617 | Robertson et al. | Nov 2004 | B2 |
6823865 | Drew et al. | Nov 2004 | B2 |
6823869 | Raje et al. | Nov 2004 | B2 |
6834650 | Fini | Dec 2004 | B1 |
6851429 | Bishop | Feb 2005 | B2 |
6860270 | Sniadach | Mar 2005 | B2 |
6895965 | Scarberry et al. | May 2005 | B2 |
6907882 | Ging et al. | Jun 2005 | B2 |
6918404 | Dias da Silva | Jul 2005 | B2 |
6926004 | Schumacher | Aug 2005 | B2 |
6938620 | Payne, Jr. | Sep 2005 | B2 |
6968844 | Liland | Nov 2005 | B2 |
6972003 | Bierman et al. | Dec 2005 | B2 |
6986352 | Frater et al. | Jan 2006 | B2 |
6997177 | Wood | Feb 2006 | B2 |
7011090 | Drew et al. | Mar 2006 | B2 |
7018362 | Bierman et al. | Mar 2006 | B2 |
7021311 | Gunaratnam et al. | Apr 2006 | B2 |
7052127 | Harrison | May 2006 | B2 |
7066586 | da Silva | Jun 2006 | B2 |
7076282 | Munro et al. | Jul 2006 | B2 |
7080645 | Genger et al. | Jul 2006 | B2 |
7101359 | Kline et al. | Sep 2006 | B2 |
7107989 | Frater et al. | Sep 2006 | B2 |
7146976 | McKown | Dec 2006 | B2 |
7152599 | Thomas | Dec 2006 | B2 |
7152601 | Barakat et al. | Dec 2006 | B2 |
7191781 | Wood | Mar 2007 | B2 |
7207328 | Altemus | Apr 2007 | B1 |
7207334 | Smart | Apr 2007 | B2 |
7210481 | Lovell et al. | May 2007 | B1 |
7237551 | Ho et al. | Jul 2007 | B2 |
7243723 | Surjaatmadja | Jul 2007 | B2 |
D550836 | Chandran et al. | Sep 2007 | S |
D552733 | Criscuolo et al. | Oct 2007 | S |
7285255 | Kadlec et al. | Oct 2007 | B2 |
7287528 | Ho | Oct 2007 | B2 |
7302950 | Berthon-Jones et al. | Dec 2007 | B2 |
7318437 | Gunaratnam et al. | Jan 2008 | B2 |
7318439 | Raje et al. | Jan 2008 | B2 |
7523754 | Lithgow | Apr 2009 | B2 |
7658189 | Davidson | Feb 2010 | B2 |
8684004 | Eiffer | Apr 2014 | B2 |
8701667 | Ho | Apr 2014 | B1 |
9937312 | Kwok | Apr 2018 | B2 |
9987450 | Veliss | Jun 2018 | B2 |
10265489 | Wells | Apr 2019 | B2 |
20010020474 | Hecker et al. | Sep 2001 | A1 |
20020005198 | Kwok et al. | Jan 2002 | A1 |
20020029780 | Frater et al. | Mar 2002 | A1 |
20020046755 | Devoss | Apr 2002 | A1 |
20020053347 | Ziaee | May 2002 | A1 |
20020066452 | Kessler et al. | Jun 2002 | A1 |
20020069872 | Gradon et al. | Jun 2002 | A1 |
20020096178 | Ziaee | Jul 2002 | A1 |
20020124849 | Billette De Villemeur | Sep 2002 | A1 |
20020143296 | Russo | Oct 2002 | A1 |
20020157673 | Kessler et al. | Oct 2002 | A1 |
20020174868 | Kwok et al. | Nov 2002 | A1 |
20020185134 | Bishop | Dec 2002 | A1 |
20030000526 | Goebel | Jan 2003 | A1 |
20030019495 | Palkon et al. | Jan 2003 | A1 |
20030019496 | Kopacko et al. | Jan 2003 | A1 |
20030075180 | Raje et al. | Apr 2003 | A1 |
20030079749 | Strickland et al. | May 2003 | A1 |
20030089373 | Gradon et al. | May 2003 | A1 |
20030111080 | Olsen et al. | Jun 2003 | A1 |
20030154980 | Berthon-Jones et al. | Aug 2003 | A1 |
20030168063 | Gambone et al. | Sep 2003 | A1 |
20030196656 | Moore et al. | Oct 2003 | A1 |
20030196658 | Ging et al. | Oct 2003 | A1 |
20040025882 | Mada et al. | Feb 2004 | A1 |
20040025885 | Payne, Jr. | Feb 2004 | A1 |
20040045551 | Eaton et al. | Mar 2004 | A1 |
20040065328 | Amarasinghe et al. | Apr 2004 | A1 |
20040106891 | Langan et al. | Jun 2004 | A1 |
20040107968 | Griffiths | Jun 2004 | A1 |
20040111104 | Schein et al. | Jun 2004 | A1 |
20040112384 | Lithgow et al. | Jun 2004 | A1 |
20040118406 | Lithgow et al. | Jun 2004 | A1 |
20040127856 | Johnson | Jul 2004 | A1 |
20040133958 | Darnell | Jul 2004 | A1 |
20040211428 | Jones, Jr. | Oct 2004 | A1 |
20040226564 | Persson | Nov 2004 | A1 |
20040226566 | Gunaratnam et al. | Nov 2004 | A1 |
20050011523 | Aylsworth et al. | Jan 2005 | A1 |
20050028822 | Sleeper et al. | Feb 2005 | A1 |
20050033247 | Thompson | Feb 2005 | A1 |
20050039757 | Wood | Feb 2005 | A1 |
20050051171 | Booth | Mar 2005 | A1 |
20050051176 | Riggins | Mar 2005 | A1 |
20050056286 | Huddart et al. | Mar 2005 | A1 |
20050061326 | Payne, Jr. | Mar 2005 | A1 |
20050101933 | Marrs et al. | May 2005 | A1 |
20050121030 | Bateman | Jun 2005 | A1 |
20050150495 | Rittner et al. | Jul 2005 | A1 |
20050155604 | Ging et al. | Jul 2005 | A1 |
20050172969 | Ging | Aug 2005 | A1 |
20050211252 | Lang et al. | Sep 2005 | A1 |
20050241644 | Gunaratnam et al. | Nov 2005 | A1 |
20050257792 | Wixey | Nov 2005 | A1 |
20050284481 | Meyer | Dec 2005 | A1 |
20060042629 | Geist | Mar 2006 | A1 |
20060060200 | Ho et al. | Mar 2006 | A1 |
20060081250 | Bordewick et al. | Apr 2006 | A1 |
20060095008 | Lampropoulos et al. | May 2006 | A1 |
20060095009 | Lampropoulos et al. | May 2006 | A1 |
20060096598 | Ho et al. | May 2006 | A1 |
20060107960 | Smart | May 2006 | A1 |
20060118117 | Berthon-Jones | Jun 2006 | A1 |
20060124131 | Chandran et al. | Jun 2006 | A1 |
20060130844 | Ho | Jun 2006 | A1 |
20060137690 | Gunaratnam et al. | Jun 2006 | A1 |
20060174887 | Chandran et al. | Aug 2006 | A1 |
20060207597 | Wright | Sep 2006 | A1 |
20060207599 | Busch | Sep 2006 | A1 |
20060237017 | Davidson et al. | Oct 2006 | A1 |
20060237018 | McAuley et al. | Oct 2006 | A1 |
20060283461 | Lubke et al. | Dec 2006 | A1 |
20060289010 | Kwok et al. | Dec 2006 | A1 |
20070023044 | Kwok et al. | Feb 2007 | A1 |
20070125387 | Zollinger et al. | Jun 2007 | A1 |
20070144525 | Davidson et al. | Jun 2007 | A1 |
20070186930 | Davidson et al. | Aug 2007 | A1 |
20070272249 | Chandran et al. | Nov 2007 | A1 |
20070282272 | Bannon et al. | Dec 2007 | A1 |
20080004573 | Kaufmann et al. | Jan 2008 | A1 |
20080006277 | Worboys et al. | Jan 2008 | A1 |
20080047560 | Veliss et al. | Feb 2008 | A1 |
20080060649 | Veliss | Mar 2008 | A1 |
20080065022 | Kyvik et al. | Mar 2008 | A1 |
20080110469 | Weinberg | May 2008 | A1 |
20080149104 | Eifler | Jun 2008 | A1 |
20080200880 | Kyvik et al. | Aug 2008 | A1 |
20080257354 | Davidson et al. | Oct 2008 | A1 |
20080314390 | Kwok | Dec 2008 | A1 |
20090014007 | Brambilla et al. | Jan 2009 | A1 |
20090044808 | Guney et al. | Feb 2009 | A1 |
20100000534 | Kooij et al. | Jan 2010 | A1 |
20100018534 | Veliss et al. | Jan 2010 | A1 |
20110146684 | Wells et al. | Jun 2011 | A1 |
20150040912 | Wells et al. | Feb 2015 | A1 |
20180140791 | Jones | May 2018 | A1 |
Number | Date | Country |
---|---|---|
199651130 | Oct 1996 | AU |
2005100738 | Nov 2005 | AU |
1553820 | Dec 2004 | CN |
1628870 | Jun 2005 | CN |
1681553 | Oct 2005 | CN |
1784250 | Jun 2006 | CN |
1901962 | Jan 2007 | CN |
101128233 | Feb 2008 | CN |
101155610 | Apr 2008 | CN |
101155618 | Apr 2008 | CN |
101389369 | Mar 2009 | CN |
185017 | May 1907 | DE |
30 11 900 | Oct 1980 | DE |
146 688 | Feb 1981 | DE |
37 19 009 | Dec 1988 | DE |
39 27 038 | Feb 1991 | DE |
297 23 101 | Jul 1998 | DE |
197 03 526 | Aug 1998 | DE |
199 44 242 | Mar 2001 | DE |
10002571 | Jul 2001 | DE |
102 13 905 | Oct 2002 | DE |
10 2004 055 433 | Nov 2004 | DE |
0 288 937 | Nov 1988 | EP |
0 427 474 | May 1991 | EP |
0 466 960 | Jan 1992 | EP |
0 303 090 | Apr 1992 | EP |
0 658 356 | Jun 1995 | EP |
0 776 679 | Jun 1997 | EP |
1 099 452 | May 2001 | EP |
1 147 782 | Oct 2001 | EP |
1 258 266 | Nov 2002 | EP |
1 481 702 | Dec 2004 | EP |
1 982 740 | Apr 2008 | EP |
1982740 | Oct 2008 | EP |
2 259 828 | Dec 2010 | EP |
2 720 280 | Dec 1995 | FR |
2 823 122 | Oct 2002 | FR |
532214 | Jan 1941 | GB |
2 176 404 | Dec 1986 | GB |
2 368 533 | May 2002 | GB |
2376896 | Dec 2002 | GB |
2 385 533 | Aug 2003 | GB |
2000-515784 | Nov 2000 | JP |
2002-028240 | Jan 2002 | JP |
2006-505373 | Feb 2006 | JP |
2006-326129 | Dec 2006 | JP |
2008-526393 | Jul 2008 | JP |
2009-520579 | May 2009 | JP |
2011-512968 | Apr 2011 | JP |
WO 1982003548 | Oct 1982 | WO |
WO 1987001950 | Apr 1987 | WO |
WO 1992020392 | Nov 1992 | WO |
WO 1992020395 | Nov 1992 | WO |
WO 1996028207 | Sep 1996 | WO |
WO 1998004310 | Feb 1998 | WO |
WO 1998012965 | Apr 1998 | WO |
WO 1998023305 | Jun 1998 | WO |
WO 1999016327 | Apr 1999 | WO |
WO 1999025410 | May 1999 | WO |
WO 1999043375 | Sep 1999 | WO |
WO 1999061088 | Dec 1999 | WO |
WO 2000020072 | Apr 2000 | WO |
WO 2000038772 | Jul 2000 | WO |
WO 2000050121 | Aug 2000 | WO |
WO 0069521 | Nov 2000 | WO |
WO 2000072905 | Dec 2000 | WO |
WO 2000074758 | Dec 2000 | WO |
WO 2000076568 | Dec 2000 | WO |
WO 2000078384 | Dec 2000 | WO |
WO 2001062326 | Aug 2001 | WO |
WO 2001095965 | Dec 2001 | WO |
WO 2001097892 | Dec 2001 | WO |
WO 2001097893 | Dec 2001 | WO |
WO 2002038221 | May 2002 | WO |
WO 2002045784 | Jun 2002 | WO |
WO 03082406 | Oct 2003 | WO |
WO 2003090827 | Nov 2003 | WO |
WO 2003105921 | Dec 2003 | WO |
WO 2004022146 | Mar 2004 | WO |
WO 2004041342 | May 2004 | WO |
WO 2004073778 | Sep 2004 | WO |
WO 2004078230 | Sep 2004 | WO |
WO 2005053781 | Jun 2005 | WO |
WO 2005063326 | Jul 2005 | WO |
WO 2005063328 | Jul 2005 | WO |
WO 2005086943 | Sep 2005 | WO |
WO 2005099801 | Oct 2005 | WO |
WO 2005110220 | Nov 2005 | WO |
WO 2005118040 | Dec 2005 | WO |
PCTAU2006000031 | Jan 2006 | WO |
PCTAU2006000417 | Mar 2006 | WO |
PCTAU2006000770 | Jun 2006 | WO |
WO 2006069415 | Jul 2006 | WO |
WO 2006074513 | Jul 2006 | WO |
WO 2006074516 | Jul 2006 | WO |
WO-2006074513 | Jul 2006 | WO |
WO 2006099658 | Sep 2006 | WO |
WO 2006113321 | Oct 2006 | WO |
WO 2006130903 | Dec 2006 | WO |
WO 2007009182 | Jan 2007 | WO |
WO 2007041751 | Apr 2007 | WO |
WO 2007041786 | Apr 2007 | WO |
WO 2007048174 | May 2007 | WO |
WO 2007053878 | May 2007 | WO |
WO 2007068044 | Jun 2007 | WO |
WO 2007115153 | Oct 2007 | WO |
WO 2007120355 | Oct 2007 | WO |
PCTAU2007001936 | Dec 2007 | WO |
WO 2007143772 | Dec 2007 | WO |
WO 2007145534 | Dec 2007 | WO |
WO 2008011682 | Jan 2008 | WO |
WO 2008011683 | Jan 2008 | WO |
WO 2008040050 | Apr 2008 | WO |
WO 2008063923 | May 2008 | WO |
WO 2008070929 | Jun 2008 | WO |
PCTAU2009000262 | Mar 2009 | WO |
WO 2009108994 | Sep 2009 | WO |
WO 2009109004 | Sep 2009 | WO |
WO 2010028425 | Mar 2010 | WO |
WO 2010148453 | Dec 2010 | WO |
Entry |
---|
NZ First Examination Report mailed Dec. 24, 2020 in corresponding NZ Application 770159 (3 pages). |
U.S. Final Office Action mailed Dec. 30, 2020 in related U.S. Appl. No. 15/987,734 (13 pages). |
Extended EP Search Report mailed Feb. 16, 2021 in related EP Application 21174225.9 (19 pages). |
Chinese Notification of the Third Office Action and English translation thereof mailed May 12, 2020 in related Chinese application 201611072310.X. |
NZ Further Examination Report mailed Jun. 17, 2020 in corresponding NZ application 754381. |
EP Summons to attend oral proceedings pursuant to Rule 115(1) EPC mailed Dec. 11, 2020 in corresponding EP Application 09812518.0 (5 pages). |
U.S. Office Action mailed Sep. 21, 2020 in related U.S. Appl. No. 15/998,734 (45 pages). |
CN Office Action and English translation thereof mailed Nov. 6, 2020 in related CN Application 201611072310.X (15 pages). |
Chinese Notification of the Second Office Action and English translation thereof mailed Sep. 5, 2019 in Chinese application 201611072310.X. |
International Preliminary Report on Patentability mailed Jul. 8, 2010 in related PCT application PCT/AU2009/000262. |
EP Communication pursuant to Article 94(3) EPC mailed Apr. 14, 2019 in related EP application 09716805.8. |
NZ First Examination Report mailed Mar. 11, 2019 in related AU application 751320. |
NZ Further Examination Report mailed May 16, 2019 in related AU application 751320. |
EP Communication pursuant to Article 94(3) EPC mailed Mar. 13, 2019 in corresponding EP Application 09812518.0. |
CN Examination Decision on Request for Reexamination and English translation thereof mailed Apr. 3, 2019 in related CN Application 201510114255.5. |
NZ First Examination Report mailed Jun. 14, 2019 in corresponding NZ application 754381. |
Third Office Action issued in corresponding Chinese Application No. 200980136031.7 on Jun. 20, 2014 with English-language translation thereof (8 pages). |
Notice of Allowance issued Apr. 28, 2014 in corresponding Japanese Application No. 2011-526353. |
Second Office Action issued in corresponding Chinese Application No. 200980136031.7 on Nov. 19, 2013 with English-language translation thereof. |
Notice of Reasons for Rejection issued in corresponding Japanese Application No. 2011-526353 on Oct. 8, 2013 with English-language translation. |
Patent Examination Report No. 1 issued in corresponding Australian Patent Application No. 2009291491 on Oct. 8, 2013. |
Chinese Office Action issued in corresponding Chinese Application No. 200980136031.7 dated Feb. 27, 2013. |
Examination Report for corresponding New Zealand Application No. 591308, mailed Jun. 21, 2012, 2 pages. |
Supplementary European Search Report issued Dec. 18, 2009 in European Application No. 03810331.3. |
International Search Report issued in PCT/AU2009/001144 (Dec. 18, 2009). |
“Ear Loop Face Mask”, USPTO to assume before Applicant's filing date. |
Adam J. Singer MD et al. “The Cyanoacrylate Topical Skin Adhesives,” American Journal of Emergency Medicine, Vol. 26, 2008, pp. 490-496. |
Webster's Third New International Dictionary, 1993, Dictionary definition for adjustable, bendable, and mild steel. |
ComfortLite™, Respironics, http://comfortlite.respironics.com, USPTO to assume before Applicant's filing date. |
ComfortLite™ 2, Respironics, http://comfortlite2.respironics.com, USPTO to assume before Applicant's filing date. |
“If You Hate CPAP! You Need CPAP Pro®,” www.cpappro.com, USPTO to assume before Applicant's filing date. |
Webster's New World Dictionary, Third College Edition 1988, definition for engaged and flexible. |
EP Supplementary Search Report issued in EP Application 03793493, dated Dec. 2, 2009. |
European Search Report filed on Jul. 27, 2009 in EP Application No. 07784697.0. |
European Search Report issued in EP 07845378.4, mailed Dec. 1, 2009. |
Examination Report filed in New Zealand Application 539836, dated Aug. 25, 2005. |
Examiner's Report No. 3 mailed Nov. 18, 2009 in New Zealand Application No. 2003275762. |
Extended European Search Report dated Mar. 19, 2009 in European Application No. EP 08161249. |
Extended European Search Report Mailed Sep. 3, 2009 in corresponding EP Application No. 09161984.1. |
Extended European Search Report. Application No. EP 08154854, dated Nov. 27, 2008. |
Fisher and Paykel Col.—Product Family—http://www.fphcare.com/osa/products.asp/, USPTO to assume before Applicant's filing date. |
Hans Rudolph, Inc.—Mask Products—http://www.rudolphkc.com/products.php?category=MASKS, USPTO to assume before Applicant's filing date. |
International Preliminary Report on Patentability for PCT/AU2004/001832, dated Jul. 3, 2006. |
International Search Report filed in PCT/AU2005/000803, dated Jun. 30, 2005. |
International Search Report filed in PCT/AU2006/000770, dated Aug. 3, 2006. |
International Search Report for PCT/AU2007/001052, dated Oct. 9, 2007. |
International Search Report for PCT/AU2007/001051, dated Nov. 5, 2007. |
International Search Report for PCT/AU2004/001832, dated Mar. 24, 2005. |
International Search Report for PCT/AU2007/001936, dated Mar. 4, 2008. |
Joel W. Beam, “Tissue Adhesives for Simple Traumatic Lacerations,” Journal of Athletic Training, 2008, vol. 43, No. 2, pp. 222-224. |
Merriam-Webster Online Dictionary definition of moveable from the 14th century. |
Office Action mailed Dec. 22, 2009 in European Appln. No. 04802133.1. |
Office Action issued in Japanese Application No. 2007-513621 (Aug. 24, 2010) with English translation. |
ResMed Co.—Mask Products—http://resmed.com/portal/site/ResMedUS/index.jsp? , USPTO to assume before Applicant's filing date. |
Respironics Co.—Mask Family—http://masksfamily.respironics.com/, USPTO to assume before Applicant's filing date. |
Snapp Nasal Interface, Tiara Medical Systems, Inc.—http://www.tiaramed.com/asp_shops/shopdisplayproducts.asp?id=109&cat=SNAPP%2A+Nasal+Interface, USPTO to assume before Applicant's filing date. |
Unsolicited email from Elson Silva, PhD, dated Mar. 28, 2008, “Requesting IDS of U.S. Pat. No. 6,766,817 for patents on fluids moving on porosity by Unsaturated Hydraulic Flow,” (email provided in both HTML and plain text format). |
International Search Report PCT/AU2003/001163, dated Nov. 4, 2003. |
International Search Report PCT/AU2003/001471, dated Feb. 12, 2004. |
International Search Report PCT/AU2009/000240, dated May 21, 2009. |
International Search Report PCT/AU2009/000262, dated Jun. 9, 2009. |
Office Action issued in European Application No. 05746824.1 (Mar. 22, 2011). |
Supplementary European Search Report mailed Dec. 18, 2009 in European Application No. 03810331.3. |
Supplementary European Search Report mailed Sep. 8, 2009 in European Appln. No. 04802133.1. |
Subbu Venkatraman et al., “Review Skin Adhesives and Skin Adhesion 1. Transdermal Drug Delivery Systems,” Biomaterials, vol. 19, 1998, pp. 1119-1136. |
Patent Examination Report No. 2 issued Nov. 26, 2014 in corresponding Australian Patent Application No. 2009291491. |
Further Examination Report issued in corresponding New Zealand Patent Appln. No. 615630, dated Mar. 20, 2015 (2 pages). |
Further Examination Report issued in corresponding New Zealand Patent Appln. No. 615630, dated Apr. 10, 2015 (2 pages). |
Patent Examination Report No. 3 issued Jun. 3, 2015 in a corresponding Australian Patent Application No. 2009291491 (3 pages). |
Requisition by the Examiner issued May 29, 2015, in a corresponding Canadian Application No. 2,735,986 (4 pages). |
Office Action issued Jun. 8, 2015 in a corresponding Japanese Patent Application No. 2014-109892 (3 pages) and English translation thereof (4 pages). |
Office Action issued Jun. 30, 2015 in a related U.S. Appl. No. 12/736,030 (13 pages). |
Communication including extended European Search Report issued Aug. 26, 2015, in a corresponding European Application No. 09 81 258.0 (11 pages). |
Notice of Opposition to Grant of Patent filed Sep. 29, 2015 in a corresponding New Zealand Application No. 615630 (5 pages). |
Further Examination Report issued Nov. 11, 2015 in a corresponding New Zealand Application No. 705201 (2 pages). |
Deadline for Counterstatement issued Jan. 5, 2016 in a corresponding New Zealand Application No. 615630 (1 page), Amended Notice of Opposition filed Nov. 27, 2015 (both markup and clean) (6 pages), and Statement of the Case filed Nov. 27, 2015 (9 pages). |
Notification of Reexamination issued Feb. 23, 2016 in a related Chinese Application No. 200980107829.9 (7 pages) and English translation thereof (8 pages). |
Patent Examination Report No. 1 issued Mar. 11, 2016 in a related Australian Application No. 2015200781 (5 pages). |
First Examination Report issued Apr. 5, 2016, in a related New Zealand Application No. 717325 (2 pages). |
First Office Action issued Jul. 28, 2016 in a related Chinese Application No. 201510114255.5 (10 pages), and an English translation thereof (10 pages). |
Notice of Allowance issued Oct. 7, 2016, in a corresponding Japanese Application No. 2015-109892 (3 pages). |
Examination Decision of the Patent Examination Board issued Aug. 30, 2016, in a related Chinese Application No. 200980107829.9 (11 pages) and an English translation thereof (12 pages). |
First Office Action issued Sep. 5, 2016, in a corresponding Chinese application No. 201510141153.2 (11 pages), and an English translation thereof (13 pages). |
Patent Examination Report No. 2 issued Nov. 24, 2016 in a related Australian Application No. 2015200781 (3 pages). |
Examination Report No. 1 issued Jan. 20, 2017, in a corresponding Australian Application No. 2015238868 (8 pages). |
Office Action issued Mar. 10, 2017 in a related U.S. Appl. No. 12/736,030 (23 pages). |
Further Examination Report issued Jun. 19, 2017 in a related New Zealand Application No. 717325 (2 pages). |
Communication Pursuant to Article 94(3) EPC issued Jun. 20, 2017, in a related European Application No. 09 716 805.8 (8 pages). |
Office Action issued Jun. 13, 2017, in a corresponding Canadian Application No. 2,941,584 (3 pages). |
Second Office Action issued Jul. 19, 2016, in a corresponding Chinese Patent Application No. 201510141153.2 (9 pages), and an English translation thereof (12 pages). |
Decision of Rejection issued Aug. 8, 2017, in a related Chinese Application No. 201510114255.5 (18 pages), and an English translation thereof (21 pages). |
Second Office Action issued Feb. 13, 2017 in a related Chinese Application No. 2015101142555 (16 pages), and an English translation thereof (19 pages). |
Final Office Action issued Sep. 21, 2017, in a related U.S. Appl. No. 12/736,030 (13 pages). |
First Examination Report issued Jul. 12, 2016, in a corresponding New Zealand Patent Application No. 719072 (3 pages). |
First Examination Report issued Sep. 22, 2017, in a related New Zealand Patent Application No. 733524 (2 pages). |
Office Action mailed Oct. 23, 2017, in a corresponding Japanese Patent Application No. 2016-216279 (2 pages), and an English translation thereof (3 pages). |
Further Examination Report issued Dec. 4, 2017, in a corresponding New Zealand Patent Application No. 719072 (1 page). |
Requisition by the Examiner issued Dec. 14, 2017, in a corresponding Canadian Patent Application No. 2,941,584 (3 pages). |
Second Examination Report dated Sep. 22, 2017 in corresponding Australian Patent Application No. 2015238868 (4 pages). |
Third Examination Report dated Jan. 16, 2018, in corresponding Australian Patent Application No. 2015238868 (4 pages). |
Third Office Action issued Feb. 8, 2018, in a corresponding Chinese Patent Application No. 2015101411532 (3 pages), and an English translation thereof (5 pages). |
First Examination Report issued Jan. 9, 2018, in a corresponding New Zealand Patent Application No. 738034 (3 page). |
Further Examination Report issued in corresponding New Zealand Application No. 738034, dated Aug. 6, 2018 (2 pages). |
Further Examination Report issued in related New Zealand Application No. 735524 dated Dec. 6, 2018, (3 pages). |
Further Examination Report issued in corresponding New Zealand Application No. 738034 dated Nov. 27, 2018, (2 pages). |
U.S. Appl. No. 10/385,701, filed Aug. 2003, Berthon-Jones et al. |
U.S. Appl. No. 10/533,928, filed Jul. 2005, Berthon-Jones. |
U.S. Appl. No. 10/584,711, filed Dec. 2004, Davidson. |
U.S. Appl. No. 10/655,622, filed Sep. 2003, Lithgow. |
U.S. Appl. No. 10/781,929, filed Jan. 2008, Gunaratnam et al. |
U.S. Appl. No. 10/871,929, filed Feb. 2004, Surjaatmadja. |
U.S. Appl. No. 11/080,446, filed Jul. 2005, Ging et al. |
U.S. Appl. No. 11/447,295, filed Jun. 2006, Lubke et al. |
U.S. Appl. No. 11/474,415, filed Jun. 2006, Davidson et al. |
U.S. Appl. No. 11/491,016, filed Feb. 2007, Kwok et al. |
U.S. Appl. No. 11/703,082, filed Feb. 2007, Davidson. |
U.S. Appl. No. 11/878,932, filed Jul. 2007, Veliss et al. |
U.S. Appl. No. 11/878,933, filed Jul. 2007, Veliss et al. |
U.S. Appl. No. 12/081,696, filed Apr. 2008, Davidson et al. |
U.S. Appl. No. 12/085,191, filed May 2008, Kwok et al. |
U.S. Appl. No. 12/219,852, filed Jul. 2008, Guney et al. |
U.S. Appl. No. 12/309,696, filed Jan. 2009, Kwok et al. |
U.S. Appl. No. 12/382,517, filed Mar. 2009, Lithgow. |
U.S. Appl. No. 12/448,250, filed Jun. 2009, Veliss et al. |
U.S. Appl. No. 12/461,448, filed Aug. 2009, Berthon-Jones. |
U.S. Appl. No. 12/478,537, filed Jun. 2009, Kooij et al. |
U.S. Appl. No. 12/656,466, filed Jan. 2010, Biener et al. |
U.S. Appl. No. 12/700,878, filed Feb. 2010, Davidson et al. |
U.S. Appl. No. 60/424,686, filed Nov. 2002, Lithgow. |
U.S. Appl. No. 60/483,622, filed Jul. 2003, Kwok et al. |
U.S. Appl. No. 60/533,214, filed Dec. 2003, Drew. |
U.S. Appl. No. 60/634,802, filed Dec. 2004, Chandran. |
U.S. Appl. No. 60/645,672, filed Jan. 2005, Chandran. |
U.S. Appl. No. 60/795,615, filed Apr. 2006, Judson et al. |
U.S. Appl. No. 60/833,841, filed Jul. 2006, Veliss. |
U.S. Appl. No. 60/835,442, filed Aug. 2006, Selvarajan et al. |
U.S. Appl. No. 60/852,649, filed Oct. 2006, Selvarajan et al. |
U.S. Appl. No. 60/874,968, filed Dec. 2006, Kwok et al. |
U.S. Appl. No. 60/907,856, filed Apr. 2007, Davidson et al. |
U.S. Appl. No. 60/924,241, filed May 2007, Kwok et al. |
U.S. Appl. No. 60/929,393, filed Jun. 2007, Kwok et al. |
U.S. Appl. No. 60/935,179, filed Jul. 2007, Guney et al. |
U.S. Appl. No. 60/935,336, filed Aug. 2007, Davidson et al. |
U.S. Appl. No. 60/996,160, filed Nov. 2007, Guney et al. |
U.S. Appl. No. 61/006,409, filed Jan. 2008, Guney et al. |
U.S. Appl. No. 61/064,818, filed Mar. 2008, Guney et al. |
U.S. Appl. No. 61/071,512, filed May 2008, Guney et al. |
U.S. Appl. No. 61/213,326, filed May 2009, Dravitzki et al. |
U.S. Appl. No. 61/222,711, filed Jul. 2009, Dravitzki et al. |
U.S. Appl. No. 61/263,175, filed Nov. 2009, Dravitzki et al. |
U.S. Appl. No. 61/272,162, filed Aug. 2009, Dravitzki et al. |
U.S. Appl. No. 61/272,250, filed Sep. 2009, Dravitzki et al. |
Number | Date | Country | |
---|---|---|---|
20190192800 A1 | Jun 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14524097 | Oct 2014 | US |
Child | 16288495 | US | |
Parent | 12737919 | US | |
Child | 14524097 | US |